TEAD4 as a Prognostic Marker Promotes Cell Migration and Invasion of Urinary Bladder Cancer via EMT

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25–41. doi:10.1038/nrc3817
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Bellmunt J, Sonpavde G, et al. ICUD-EAU International consultation on bladder cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013;63(1):58–66. doi:10.1016/j.eururo.2012.08.010
   PubMed Web of Science ®Google Scholar
• Kluth LA, Black PC, Bochner BH, et al. Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature. Eur Urol. 2015;68(2):238–253. doi:10.1016/j.eururo.2015.01.032
   PubMed Web of Science ®Google Scholar
• Dey A, Varelas X, Guan KL. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020;19(7):480–494. doi:10.1038/s41573-020-0070-z
   PubMed Web of Science ®Google Scholar
• Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163(4):811–828. doi:10.1016/j.cell.2015.10.044
   PubMed Web of Science ®Google Scholar
• Zheng Y, Pan D. The hippo signaling pathway in development and disease. Dev Cell. 2019;50(3):264–282.
   PubMed Web of Science ®Google Scholar
• Calses PC, Crawford JJ, Lill JR, Dey A. Hippo pathway in cancer: aberrant regulation and therapeutic opportunities. Trends Cancer. 2019;5(5):297–307. doi:10.1016/j.trecan.2019.04.001
   PubMed Web of Science ®Google Scholar
• Ma S, Meng Z, Chen R, Guan KL. The hippo pathway: biology and pathophysiology. Annu Rev Biochem. 2019;88:577–604. doi:10.1146/annurev-biochem-013118-111829
   PubMed Web of Science ®Google Scholar
• Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell. 2016;29(6):783–803. doi:10.1016/j.ccell.2016.05.005
   PubMed Web of Science ®Google Scholar
• Koo JH, Guan KL. Interplay between YAP/TAZ and metabolism. Cell Metab. 2018;28(2):196–206. doi:10.1016/j.cmet.2018.07.010
   PubMed Web of Science ®Google Scholar
• Pobbati AV, Hong W. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020;10(8):3622–3635. doi:10.7150/thno.40889
   PubMed Web of Science ®Google Scholar
• Lin KC, Park HW, Guan KL. Regulation of the hippo pathway transcription factor TEAD. Trends Biochem Sci. 2017;42(11):862–872. doi:10.1016/j.tibs.2017.09.003
   PubMed Web of Science ®Google Scholar
• Holden JK, Cunningham CN. Targeting the hippo pathway and cancer through the TEAD family of transcription factors. Cancers. 2018;10:3. doi:10.3390/cancers10030081
   Web of Science ®Google Scholar
• Gibault F, Sturbaut M, Bailly F, Melnyk P, Cotelle P. Targeting Transcriptional Enhanced Associate Domains (TEADs). J Med Chem. 2018;61(12):5057–5072. doi:10.1021/acs.jmedchem.7b00879
   PubMed Web of Science ®Google Scholar
• Huh HD, Kim DH, Jeong HS, Park HW. Regulation of TEAD transcription factors in cancer biology. Cells. 2019;8:6. doi:10.3390/cells8060600
   Web of Science ®Google Scholar
• Zhou Y, Huang T, Cheng AS, Yu J, Kang W, To KF. The TEAD family and its oncogenic role in promoting tumorigenesis. Int J Mol Sci. 2016;17:1.
   Web of Science ®Google Scholar
• Pobbati AV, Hong W. Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther. 2013;14(5):390–398. doi:10.4161/cbt.23788
   PubMed Web of Science ®Google Scholar
• Marti P, Stein C, Blumer T, et al. YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. Hepatology. 2015;62(5):1497–1510. doi:10.1002/hep.27992
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang G, Yang Y, et al. Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner. Oncogene. 2016;35(21):2789–2800. doi:10.1038/onc.2015.342
   PubMed Web of Science ®Google Scholar
• Tang J-Y, Yu C-Y, Bao Y-J, et al. TEAD4 promotes colorectal tumorigenesis via transcriptionally targeting YAP1. Cell Cycle. 2018;17(1):102–109. doi:10.1080/15384101.2017.1403687
   PubMed Web of Science ®Google Scholar
• Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A. 2012;109(37):E2441–2450. doi:10.1073/pnas.1212021109
   PubMed Web of Science ®Google Scholar
• Zhou Y, Huang T, Zhang J, et al. TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis. Oncogene. 2017;36(47):6518–6530. doi:10.1038/onc.2017.257
   PubMed Web of Science ®Google Scholar
• Yan YL, Huang ZN, Zhu Z, et al. Downregulation of TET1 promotes bladder cancer cell proliferation and invasion by reducing DNA hydroxymethylation of AJAP1. Front Oncol. 2020;10:667. doi:10.3389/fonc.2020.00667
   PubMed Web of Science ®Google Scholar
• Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84. doi:10.1038/s41580-018-0080-4
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell. 2016;166(1):21–45.
   PubMed Web of Science ®Google Scholar
• Knight JF, Shepherd CJ, Rizzo S, et al. TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer. 2008;99(11):1849–1858. doi:10.1038/sj.bjc.6604774
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Kasamatsu A, Yamatoji M, et al. TEAD4-YAP interaction regulates tumoral growth by controlling cell-cycle arrest at the G1 phase. Biochem Biophys Res Commun. 2017;486(2):385–390. doi:10.1016/j.bbrc.2017.03.050
   PubMed Web of Science ®Google Scholar
• Fernandez LA, Northcott PA, Dalton J, et al. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev. 2009;23(23):2729–2741. doi:10.1101/gad.1824509
   PubMed Web of Science ®Google Scholar
• Gu C, Huang Z, Chen X, et al. TEAD4 promotes tumor development in patients with lung adenocarcinoma via ERK signaling pathway. Biochimica et Biophysica Acta. 2020;1866:12. doi:10.1016/j.bbadis.2020.165921
   Web of Science ®Google Scholar
• Zhang W, Li J, Wu Y, et al. TEAD4 overexpression promotes epithelial-mesenchymal transition and associates with aggressiveness and adverse prognosis in head neck squamous cell carcinoma. Cancer Cell Int. 2018;18:178. doi:10.1186/s12935-018-0675-z
   PubMed Web of Science ®Google Scholar
• Wu Y, Zheng Q, Li Y, et al. Metformin targets a YAP1-TEAD4 complex via AMPKalpha to regulate CCNE1/2 in bladder cancer cells. J Exp Clin Cancer Res. 2019;38(1):376. doi:10.1186/s13046-019-1346-1
   PubMed Web of Science ®Google Scholar
• He L, Yuan L, Sun Y, et al. Glucocorticoid receptor signaling activates TEAD4 to promote breast cancer progression. Cancer Res. 2019;79(17):4399–4411. doi:10.1158/0008-5472.CAN-19-0012
   PubMed Web of Science ®Google Scholar
• De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97–110. doi:10.1038/nrc3447
   PubMed Web of Science ®Google Scholar
• Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 2017;11(1):28–39. doi:10.1002/1878-0261.12017
   PubMed Web of Science ®Google Scholar
• Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 2018;13:395–412. doi:10.1146/annurev-pathol-020117-043854
   PubMed Web of Science ®Google Scholar
• Shen L, Zhang F, Huang R, Yan J, Shen B. Honokiol inhibits bladder cancer cell invasion through repressing SRC-3 expression and epithelial-mesenchymal transition. Oncol Lett. 2017;14(4):4294–4300. doi:10.3892/ol.2017.6665
   PubMed Web of Science ®Google Scholar
• Shiota M, Song Y, Yokomizo A, et al. Foxo3a suppression of urothelial cancer invasiveness through Twist1, Y-box-binding protein 1, and E-cadherin regulation. Clin Cancer Res. 2010;16(23):5654–5663. doi:10.1158/1078-0432.CCR-10-0376
   PubMed Web of Science ®Google Scholar